Sandoz's biosimilar etanercept enters late-stage study

06/25/2013 | Reuters · RTT News

Novartis' generics unit Sandoz initiated a late-stage trial to confirm the biosimilarity of its version of etanercept with Amgen's Enbrel. The international trial will involve the treatment of moderate to severe chronic plaque-type psoriasis. Sandoz intends to use the results to support regulatory filings in the U.S. and Europe.

View Full Article in:

Reuters · RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations